Skip Navigation


Rheumatology Advance Access originally published online on July 20, 2004
Rheumatology 2004 43(11):1383-1385; doi:10.1093/rheumatology/keh325
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary data
Right arrow All Versions of this Article:
43/11/1383    most recent
keh325v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lampropoulos, C. E.
Right arrow Articles by D'Cruz, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lampropoulos, C. E.
Right arrow Articles by D'Cruz, D. P.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 11 © British Society for Rheumatology 2004; all rights reserved

PAPER

Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative

C. E. Lampropoulos, S. Sangle, P. Harrison, G. R. V. Hughes and D. P. D'Cruz

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK.

Correspondence to: D. P. D’Cruz, The Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London SE1 7EH, UK. E-mail: david.d'cruz{at}kcl.ac.uk

Objective. To determine the efficacy of tacrolimus ointment 0.1% on resistant cutaneous lesions in patients with lupus erythematosus.

Methods. Twelve patients with skin manifestations were studied. Six had discoid lupus (DL), four subacute cutaneous lupus erythematosus (SCLE) and two systemic lupus erythematosus (SLE). All patients had extensive skin lesions refractory to previous treatment. Patients received topical tacrolimus 0.1% for a minimum of 6 weeks and response was evaluated by physicians’ and patients’ assessment and documented with photographs at baseline and at the end of the treatment.

Results. Eleven of 12 patients completed the therapy. One patient with DL discontinued because of side-effects—peeling and a burning sensation. Six patients were clearly improved, one patient had a minor remission of his face lesion while in four the rashes remained the same. Two patients with SCLE had significant regression of their lesions while the other two had no improvement. In DL, two had certain improvement, one minor improvement and two were without response. The patients with SLE had significant amelioration of their extensive photosensitive rash.

Conclusion. Tacrolimus ointment 0.1% may be an effective alternative in patients with severe resistant cutaneous manifestations in lupus erythematosus.

KEY WORDS: Tacrolimus, Cutaneous lupus erythematosus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. Tlacuilo-Parra, E. Guevara-Gutierrez, F. Gutierrez-Murillo, A. Soto-Ortiz, F. Barba-Gomez, M. Hernandez-Torres, and M. Salazar-Paramo
Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus
Rheumatology, December 1, 2005; 44(12): 1564 - 1568.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.